Following the introduction of a new CRM system in their national companies, Daiichi Sankyo Europe has set itself the task of mapping its sales and marketing activities across Europe into QlikView and Qlik Sense. As part of the project, Vision11 has taken on the requirements management at the market level and applied the implementations in the area of ETL (MS SQL) and reporting.
- More efficient field sales force management and visibility into field sales activities
- Visualization of sales data and representation of a complex data model in reports that are easy to understand
- Improvement of data quality in the CRM system
- Data flow in the database with SSIS (SQL Server Integration Services) organized and designed by MS SQL (easy maintainability)
Steps & Highlights
Vision11 took over the management of the international project. This included the project management as well as the coordination between external service providers, the software supplier Qlik and the respective Daiichi Sankyo country managers. Professionally, Vision11 was entrusted with the requirements management, which was followed by the project realization with the creation of the proof of concept and the prototype. Before the go-live, the key users from the respective markets were trained.
The main objective of the project was the introduction of a data base to enable Europe-wide uniform analyzes, reports and dashboards in sales and marketing. The particular challenge was the design of the technical data model, which should be the basis for all 12 countries. In addition, the implementation of an ETL process for a new data warehouse system, based on MS SQL, was crucial for the project’s success. The technical requirements were implemented with the Qlik Analytics applications (QlikView, Qlik Sense and QlikView Publisher). Vision11 supported the sizing of the QlikView server and created an overview of future applications.
Daiichi Sankyo develops and manufactures innovative medicines to provide effective therapies for previously poorly-treated conditions. This applies to patients in industrialized countries as well as to people in emerging and developing countries. The company markets drugs for hypertension, hyperlipidemia, bacterial infections and antithrombotic events in patients with acute coronary syndrome and percutaneous coronary intervention. In their research and development, Daiichi Sankyo focuses on novel therapies in the areas of thrombotic diseases, oncology, cardiovascular and metabolic diseases.